PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside.
CD274
PD-L1
meta-analysis
oral cancer
oral squamous cell carcinoma
programmed death-ligand 1
Journal
Clinical and experimental dental research
ISSN: 2057-4347
Titre abrégé: Clin Exp Dent Res
Pays: United States
ID NLM: 101692332
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
24
04
2022
received:
02
03
2022
accepted:
01
05
2022
pubmed:
21
5
2022
medline:
23
6
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
Oral squamous cell carcinoma (OSCC) is a highly malignant disease with an increasing incidence. The need to improve therapeutic strategies for patients affected by OSCC is an urgent challenge. Currently, the advent of immunotherapy represents an important step toward this aim. Programmed cell death-ligand 1 (PD-L1), a membrane protein that can be expressed on tumor and inflammatory cells is a key biomarker whose expression is determined by means of immunohistochemistry and is necessary for selecting patients for immunotherapy. In this study, we review the methods of PD-L1 assessment and outcomes achieved with immunotherapy in the treatment of OSCC patients. Based on a meta-analysis we demonstrate a lack of prognostic significance of PD-L1 in OSCC. We also highlight unresolved issues including difficulties in standardizing PD-L1 evaluation and discuss future opportunities such as leveraging digital pathology.
Sections du résumé
OBJECTIVES AND BACKGROUND
Oral squamous cell carcinoma (OSCC) is a highly malignant disease with an increasing incidence. The need to improve therapeutic strategies for patients affected by OSCC is an urgent challenge. Currently, the advent of immunotherapy represents an important step toward this aim. Programmed cell death-ligand 1 (PD-L1), a membrane protein that can be expressed on tumor and inflammatory cells is a key biomarker whose expression is determined by means of immunohistochemistry and is necessary for selecting patients for immunotherapy.
METHODS
In this study, we review the methods of PD-L1 assessment and outcomes achieved with immunotherapy in the treatment of OSCC patients.
RESULTS
Based on a meta-analysis we demonstrate a lack of prognostic significance of PD-L1 in OSCC.
CONCLUSIONS
We also highlight unresolved issues including difficulties in standardizing PD-L1 evaluation and discuss future opportunities such as leveraging digital pathology.
Identifiants
pubmed: 35593124
doi: 10.1002/cre2.590
pmc: PMC9209791
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
690-698Informations de copyright
© 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.
Références
Cancers (Basel). 2021 Jan 14;13(2):
pubmed: 33466794
Oral Dis. 2021 Mar;27(2):173-182
pubmed: 32583572
Hum Pathol. 2018 Oct;80:28-39
pubmed: 29634978
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMC Cancer. 2021 May 17;21(1):561
pubmed: 34001010
Sci Rep. 2020 Jun 16;10(1):9705
pubmed: 32546692
Pathol Res Pract. 2021 Oct;226:153605
pubmed: 34530257
Head Neck. 2020 Oct;42(10):3018-3030
pubmed: 32567746
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Endocr Pathol. 2020 Sep;31(3):291-300
pubmed: 32468210
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683809
Histopathology. 2022 Jan;80(2):397-406
pubmed: 34496080
J Thorac Oncol. 2019 Oct;14(10):1818-1827
pubmed: 31260834
JTO Clin Res Rep. 2020 Oct 05;2(2):100102
pubmed: 34589980
Pathol Res Pract. 2019 Jun;215(6):152418
pubmed: 31027907
Aging (Albany NY). 2020 Dec 9;13(2):2279-2293
pubmed: 33318295
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Front Immunol. 2021 Sep 06;12:693881
pubmed: 34552581
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Oral Oncol. 2020 Jul;106:104722
pubmed: 32330687
Am J Surg Pathol. 2021 Aug 1;45(8):1108-1117
pubmed: 34232604
Sci Rep. 2021 Apr 20;11(1):8551
pubmed: 33879814
Pathology. 2021 Feb;53(2):141-156
pubmed: 33388161
Biomedicines. 2021 Feb 16;9(2):
pubmed: 33669300
Pathology. 2016 Oct;48(6):574-80
pubmed: 27590194
NPJ Genom Med. 2021 May 12;6(1):32
pubmed: 33980865
Oral Dis. 2020 Apr;26(3):511-526
pubmed: 30866171
Oral Oncol. 2011 Dec;47(12):1148-53
pubmed: 21911310
Biomedicines. 2021 Sep 01;9(9):
pubmed: 34572318
Arch Oral Biol. 2020 Nov;119:104916
pubmed: 32977151
Virchows Arch. 2021 Jun;478(6):1039-1048
pubmed: 33098489
Oral Oncol. 2019 Dec;99:104460
pubmed: 31683169
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Oncol Lett. 2021 Nov;22(5):778
pubmed: 34594419
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Indian J Surg Oncol. 2021 Jun;12(2):408-414
pubmed: 34295087
Cancers (Basel). 2021 May 24;13(11):
pubmed: 34073885
Cancer Manag Res. 2021 Aug 25;13:6705-6719
pubmed: 34471384
Clin Exp Dent Res. 2022 Jun;8(3):690-698
pubmed: 35593124
Hum Pathol. 2018 Nov;81:157-165
pubmed: 30031096
Oncotarget. 2015 Aug 28;6(25):20902-20
pubmed: 26041877
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):546-554
pubmed: 30487133
Cell Prolif. 2019 Mar;52(2):e12537
pubmed: 30443950
Cancer Res. 2017 Nov 15;77(22):6365-6374
pubmed: 28947422
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Carcinogenesis. 2021 Jun 21;42(6):891-902
pubmed: 33993220
Anticancer Res. 2017 Mar;37(3):1417-1424
pubmed: 28314313
J Oral Pathol Med. 2021 Oct;50(9):864-873
pubmed: 34157159
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Oncotarget. 2016 Mar 15;7(11):12024-34
pubmed: 26918453